STANDARD_NAME	HUMMEL_BURKITTS_LYMPHOMA_DN
SYSTEMATIC_NAME	M18181
COLLECTION	C2:CGP
MSIGDB_URL	https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HUMMEL_BURKITTS_LYMPHOMA_DN
NAMESPACE	AFFY_HG_U133
DESCRIPTION_BRIEF	Down-regulated genes constituting the molecular signature of Burkitt 's lymphoma.
DESCRIPTION_FULL	BACKGROUND: The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more precisely and to distinguish subgroups in other types of mature aggressive B-cell lymphomas. METHODS: We performed gene-expression profiling using Affymetrix U133A GeneChips with RNA from 220 mature aggressive B-cell lymphomas, including a core group of 8 Burkitt's lymphomas that met all World Health Organization (WHO) criteria. A molecular signature for Burkitt's lymphoma was generated, and chromosomal abnormalities were detected with interphase fluorescence in situ hybridization and array-based comparative genomic hybridization. RESULTS: We used the molecular signature for Burkitt's lymphoma to identify 44 cases: 11 had the morphologic features of diffuse large-B-cell lymphomas, 4 were unclassifiable mature aggressive B-cell lymphomas, and 29 had a classic or atypical Burkitt's morphologic appearance. Also, five did not have a detectable IG-myc Burkitt's translocation, whereas the others contained an IG-myc fusion, mostly in simple karyotypes. Of the 176 lymphomas without the molecular signature for Burkitt's lymphoma, 155 were diffuse large-B-cell lymphomas. Of these 155 cases, 21 percent had a chromosomal breakpoint at the myc locus associated with complex chromosomal changes and an unfavorable clinical course. CONCLUSIONS: Our molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the WHO criteria for Burkitt's lymphoma. In mature aggressive B-cell lymphomas without a gene signature for Burkitt's lymphoma, chromosomal breakpoints at the myc locus were associated with an adverse clinical outcome.
PMID	16760442
GEOID	GSE4475
AUTHORS	Hummel M,Bentink S,Berger H,Klapper W,Wessendorf S,Barth TF,Bernd HW,Cogliatti SB,Dierlamm J,Feller AC,Hansmann ML,Haralambieva E,Harder L,Hasenclever D,Kühn M,Lenze D,Lichter P,Martin-Subero JI,Möller P,Müller-Hermelink HK,Ott G,Parwaresch RM,Pott C,Rosenwald A,Rosolowski M,Schwaenen C,Stürzenhofecker B,Szczepanowski M,Trautmann H,Wacker HH,Spang R,Loeffler M,Trümper L,Stein H,Siebert R,Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe
CONTRIBUTOR	Arthur Liberzon
CONTRIBUTOR_ORG	MSigDB Team
EXACT_SOURCE	Table 5.3.2S
FILTERED_BY_SIMILARITY	
EXTERNAL_NAMES_FOR_SIMILAR_TERMS	
EXTERNAL_DETAILS_URL	
SOURCE_MEMBERS	200660_at,201471_s_at,201502_s_at,202295_s_at,204489_s_at,204490_s_at,204882_at,204908_s_at,205081_at,205681_at,208991_at,208992_s_at,209835_x_at,210563_x_at,211317_s_at,211675_s_at,211862_x_at,212014_x_at,212063_at,212288_at,213142_x_at,215346_at,222150_s_at,38149_at
GENE_SYMBOLS	S100A11,SQSTM1,NFKBIA,CTSH,CD44,CD44,ARHGAP25,BCL3,CRIP1,BCL2A1,STAT3,STAT3,CD44,CFLAR,CFLAR,MDFIC,CFLAR,CD44,CD44,FNBP1,GSAP,CD40,GSAP,ARHGAP25
FOUNDER_NAMES